New drug combo aims to tame tough pancreatic cancer
NCT ID NCT05273554
First seen Jan 12, 2026 · Last updated May 15, 2026 · Updated 15 times
Summary
This early study tests whether combining two drugs, pembrolizumab and lenvatinib, can help control advanced pancreatic cancer that has not responded to prior treatment. About 15 adults with metastatic pancreatic adenocarcinoma will receive the combination. The goal is to see if the treatment shrinks tumors or slows disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.